Production (Stage)
Aligos Therapeutics, Inc.
ALGS
$5.50
-$0.17-3.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -50.56% | -50.43% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -50.56% | -50.43% | |||
| Cost of Revenue | -9.54% | -4.43% | |||
| Gross Profit | 7.86% | 0.66% | |||
| SG&A Expenses | -2.11% | 11.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.73% | -0.97% | |||
| Operating Income | 6.42% | -2.15% | |||
| Income Before Tax | 152.52% | -328.44% | |||
| Income Tax Expenses | 59.26% | -70.33% | |||
| Earnings from Continuing Operations | 152.45% | -326.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 152.45% | -326.55% | |||
| EBIT | 6.42% | -2.15% | |||
| EBITDA | 6.26% | -2.21% | |||
| EPS Basic | 139.19% | -325.89% | |||
| Normalized Basic EPS | 139.24% | -327.77% | |||
| EPS Diluted | 83.86% | -325.89% | |||
| Normalized Diluted EPS | 137.88% | -327.77% | |||
| Average Basic Shares Outstanding | 33.85% | 0.16% | |||
| Average Diluted Shares Outstanding | 38.64% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||